Search
Bivatuzumab
go.drugbank.com/drugs/DB06550InvestigationalBivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]
Pascolizumab
go.drugbank.com/drugs/DB06560InvestigationalPascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Tonabersat
go.drugbank.com/drugs/DB06578InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingMidostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 InducersSynonyms: 4'-N-benzoylstaurosporineLexatumumab
go.drugbank.com/drugs/DB06599InvestigationalLexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic … It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: ELIQUIS® 5 MG, MANTIXA® 5 TABLETAS RECUBIERTASAmdoxovir
go.drugbank.com/drugs/DB06619InvestigationalSynonyms: beta-D-2,6-Diaminopurine-dioxolaneCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingARG201
go.drugbank.com/drugs/DB06621ExperimentalARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)